Gabriela Ortiz-omphroy Md Llc | |
98-1079 Moanalua Rd Ste 680 Aiea HI 96701-4725 | |
(808) 488-4342 | |
(808) 488-4151 |
Full Name | Gabriela Ortiz-omphroy Md Llc |
---|---|
Speciality | Family Medicine |
Location | 98-1079 Moanalua Rd Ste 680, Aiea, Hawaii |
Authorized Official Name and Position | Gabriela M Ortiz-omphroy (OWNER) |
Authorized Official Contact | 8084884342 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Gabriela Ortiz-omphroy Md Llc 98-1079 Moanalua Rd Ste 680 Aiea HI 96701-4725 Ph: (808) 488-4342 | Gabriela Ortiz-omphroy Md Llc 98-1079 Moanalua Rd Ste 680 Aiea HI 96701-4725 Ph: (808) 488-4342 |
NPI Number | 1285994525 |
---|---|
Provider Enumeration Date | 05/21/2012 |
Last Update Date | 08/30/2012 |
Medicare PECOS PAC ID | 5991952012 |
---|---|
Medicare Enrollment ID | O20120824000472 |
News Archive
Using fragments of circulating tumor DNA in blood, University of California San Diego School of Medicine researchers were able to identify theoretically targetable genetic alterations in 66 percent of patients with cancer of unknown primary (CUP), a rare disease with seven to 12 cases per 100,000 people each year.
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital Cancer Center may have found at least one reason why.
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.
A new supercomputer rating system will be released by an international team led by Sandia National Laboratories at the Supercomputing Conference 2010 in New Orleans on Nov. 17.
› Verified 1 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1285994525 | NPI | - | NPPES |
53927313 | Medicaid | HI |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 12351 (Hawaii) | Primary |
Provider Name | Catherine J Tsang |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1154525368 PECOS PAC ID: 5395891725 Enrollment ID: I20090925000396 |
News Archive
Using fragments of circulating tumor DNA in blood, University of California San Diego School of Medicine researchers were able to identify theoretically targetable genetic alterations in 66 percent of patients with cancer of unknown primary (CUP), a rare disease with seven to 12 cases per 100,000 people each year.
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital Cancer Center may have found at least one reason why.
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.
A new supercomputer rating system will be released by an international team led by Sandia National Laboratories at the Supercomputing Conference 2010 in New Orleans on Nov. 17.
› Verified 1 days ago
Provider Name | Gabriela M Ortiz Omphroy |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1093879884 PECOS PAC ID: 6002708153 Enrollment ID: I20100924000147 |
News Archive
Using fragments of circulating tumor DNA in blood, University of California San Diego School of Medicine researchers were able to identify theoretically targetable genetic alterations in 66 percent of patients with cancer of unknown primary (CUP), a rare disease with seven to 12 cases per 100,000 people each year.
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital Cancer Center may have found at least one reason why.
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.
A new supercomputer rating system will be released by an international team led by Sandia National Laboratories at the Supercomputing Conference 2010 in New Orleans on Nov. 17.
› Verified 1 days ago
Provider Name | Melyssa Majano |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871039891 PECOS PAC ID: 0345514790 Enrollment ID: I20170922002292 |
News Archive
Using fragments of circulating tumor DNA in blood, University of California San Diego School of Medicine researchers were able to identify theoretically targetable genetic alterations in 66 percent of patients with cancer of unknown primary (CUP), a rare disease with seven to 12 cases per 100,000 people each year.
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital Cancer Center may have found at least one reason why.
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.
A new supercomputer rating system will be released by an international team led by Sandia National Laboratories at the Supercomputing Conference 2010 in New Orleans on Nov. 17.
› Verified 1 days ago
News Archive
Using fragments of circulating tumor DNA in blood, University of California San Diego School of Medicine researchers were able to identify theoretically targetable genetic alterations in 66 percent of patients with cancer of unknown primary (CUP), a rare disease with seven to 12 cases per 100,000 people each year.
A new study led by the Universities of Sheffield and Oxford with support from the UK Coronavirus Immunology Consortium (UK-CIC) has found that 99 per cent of people generate a robust immune response against Covid-19 after just one dose of the Pfizer vaccine.
While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital Cancer Center may have found at least one reason why.
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.
A new supercomputer rating system will be released by an international team led by Sandia National Laboratories at the Supercomputing Conference 2010 in New Orleans on Nov. 17.
› Verified 1 days ago
Rice Consultancy Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-211 Pali Momi St, Suite 312, Aiea, HI 96701 Phone: 808-486-0449 Fax: 808-488-0725 | |
Ky Le Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-1079 Moanalua Rd, Aiea, HI 96701 Phone: 808-536-0300 | |
Yousif A-rahim Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-211 Pali Momi St, 312, Aiea, HI 96701 Phone: 808-486-0449 Fax: 808-488-0725 | |
Luis J. Ragunton, M.d., Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-1079 Moanalua Rd, Suite 440, Aiea, HI 96701 Phone: 808-488-8750 Fax: 808-487-5910 | |
Mark A Morisaki Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-1079 Moanalua Rd Ste 620, Aiea, HI 96701 Phone: 808-488-2224 | |
Randall J. Nitta, Md, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-1247 Kaahumanu St Ste 306, Aiea, HI 96701 Phone: 808-484-2904 Fax: 808-484-2864 | |
Robert Wong, Md, L.l.c. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 98-211 Pali Momi Street, Suite 312, Aiea, HI 96701 Phone: 808-486-0449 Fax: 808-488-0725 |